<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923960</url>
  </required_header>
  <id_info>
    <org_study_id>BL33</org_study_id>
    <nct_id>NCT02923960</nct_id>
  </id_info>
  <brief_title>Effect of Nutritional Products in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blinded, multi treatment, crossover study intended to compare&#xD;
      the glycemic and insulinemic response after consuming liquid nutritional products in people&#xD;
      with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Glucose Concentration</measure>
    <time_frame>0 to 240 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin Concentration</measure>
    <time_frame>0 to 240 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard ONS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liquid oral nutritional supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes specific ONS 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liquid oral nutritional supplement with novel carbohydrate blend</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes specific ONS 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liquid oral nutritional supplement with novel carbohydrate blend</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard ONS</intervention_name>
    <description>One serving (237 ml) standard oral nutritional beverage</description>
    <arm_group_label>Standard ONS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diabetes specific ONS 1</intervention_name>
    <description>One serving (237 ml) diabetes oral nutritional beverage</description>
    <arm_group_label>Diabetes specific ONS 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diabetes specific ONS 2</intervention_name>
    <description>One serving (296 ml) diabetes oral nutritional beverage</description>
    <arm_group_label>Diabetes specific ONS 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has type 2 diabetes&#xD;
&#xD;
          -  Subject is a male or a nonpregnant, nonlactating female, at least 6 weeks postpartum&#xD;
             prior to screening visit&#xD;
&#xD;
          -  Subject's BMI is &gt; 18.5 kg/m2 and &lt; 35 kg/m2&#xD;
&#xD;
          -  If on a chronic medication such as antihypertensive, lipid lowering, thyroid&#xD;
             medication or hormone therapy, subject has been on constant dosage for at least two&#xD;
             months prior to screening visit&#xD;
&#xD;
          -  Subject states willingness to follow protocol as described, including consumption of&#xD;
             study product per protocol and completing any required study forms&#xD;
&#xD;
          -  Participant must refrain from taking medications/dietary supplements/herbals or&#xD;
             substances that could modulate glucose metabolism (other than oral hypoglycemic&#xD;
             medications), or considered anabolic, or reduce weight (fat mass)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is currently diagnosed with, or has a history of severe dementia or delirium,&#xD;
             eating disorder, history of significant neurological or psychiatric disorder,&#xD;
             alcoholism, substance abuse or other conditions that may interfere with study product&#xD;
             consumption or compliance with study protocol procedures&#xD;
&#xD;
          -  Subject is known to be allergic or intolerant to any ingredient found in the study&#xD;
             products&#xD;
&#xD;
          -  Subject is participating in another study that has not been approved as a concomitant&#xD;
             study&#xD;
&#xD;
          -  Subject uses exogenous insulin for glucose control, or subject states that they have&#xD;
             been diagnosed as having Type 1 diabetes&#xD;
&#xD;
          -  Subject states they have a history of diabetic ketoacidosis&#xD;
&#xD;
          -  Subject is currently on a low carbohydrate or very low carbohydrate diet&#xD;
&#xD;
          -  Subject states that he/she has a current infection; has had inpatient surgery, or&#xD;
             corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks prior&#xD;
             to screening visit&#xD;
&#xD;
          -  Subject states that he/she has an active malignancy&#xD;
&#xD;
          -  Subject states that he/she has had a significant cardiovascular event ≤ six months&#xD;
             prior to screening visit; or stated history of congestive heart failure&#xD;
&#xD;
          -  Subject states that he/she has end stage organ failure or is status post organ&#xD;
             transplant&#xD;
&#xD;
          -  Subject is diagnosed with chronic kidney disease, or a history of kidney issues&#xD;
&#xD;
          -  Subject states they have impaired liver function, or have a history of liver disease&#xD;
&#xD;
          -  Subject has an obstruction of the gastrointestinal tract precluding ingestion of the&#xD;
             study product, inflammatory bowel disease, short bowel syndrome or other severe forms&#xD;
             of gastrointestinal disease such as gastroesophageal reflux disease, gastroparesis,&#xD;
             peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, or&#xD;
             ischemic colitis, or any other related condition that may cause unnecessary subject&#xD;
             discomfort&#xD;
&#xD;
          -  Subject states they have a chronic, contagious, infectious disease&#xD;
&#xD;
          -  Subject has taken/is currently taking any herbals, dietary supplements, or medications&#xD;
             during the past four weeks prior to screening visit that are designed to affect blood&#xD;
             glucose.&#xD;
&#xD;
          -  Subject states that he/she has clotting or bleeding disorders&#xD;
&#xD;
          -  If selected for continuous blood glucose monitoring, subject has skin lesions,&#xD;
             hyperhidrosis, eczema, psoriasis, scarring, redness, infection or edema at the flash&#xD;
             constant glucose monitoring application site(s) that could interfere with device&#xD;
             placement or the accuracy of interstitial glucose measurements.&#xD;
&#xD;
          -  If selected for continuous blood glucose monitoring, subject has an X-ray, MRI or CT&#xD;
             appointment scheduled during the period of study participation, or another procedure&#xD;
             that would require removal of the flash constant glucose monitoring sensor.&#xD;
&#xD;
          -  Subjects on sulfonylureas, meglitinides, and α-glucosidase inhibitors, insulin, or&#xD;
             subject on more than two oral hypoglycemic medications excluding aforementioned.&#xD;
&#xD;
          -  Subjects on oral hypoglycemic medications that has changed in last 2 months.&#xD;
&#xD;
          -  Subject's HbA1c, per point of care device is &gt; 8%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen Kelly, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

